These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31453767)

  • 1. A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis.
    Gonsalves CF; Eschelman DJ; Adamo RD; Anne PR; Orloff MM; Terai M; Hage AN; Yi M; Chervoneva I; Sato T
    Radiology; 2019 Oct; 293(1):223-231. PubMed ID: 31453767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series.
    Zheng J; Irani Z; Lawrence D; Flaherty K; Arellano RS
    J Vasc Interv Radiol; 2018 Oct; 29(10):1369-1375. PubMed ID: 30174161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.
    Klingenstein A; Haug AR; Zech CJ; Schaller UC
    Cardiovasc Intervent Radiol; 2013 Feb; 36(1):158-65. PubMed ID: 22526099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience.
    Gonsalves CF; Eschelman DJ; Sullivan KL; Anne PR; Doyle L; Sato T
    AJR Am J Roentgenol; 2011 Feb; 196(2):468-73. PubMed ID: 21257902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
    Wong TY; Zhang KS; Gandhi RT; Collins ZS; O'Hara R; Wang EA; Vaheesan K; Matsuoka L; Sze DY; Kennedy AS; Brown DB
    BMC Cancer; 2022 Mar; 22(1):224. PubMed ID: 35232410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases.
    Arulananda S; Parakh S; Palmer J; Goodwin M; Andrews MC; Cebon J
    Cancer Rep (Hoboken); 2019 Aug; 2(4):e1183. PubMed ID: 32721131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
    Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
    Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography.
    Eldredge-Hindy H; Ohri N; Anne PR; Eschelman D; Gonsalves C; Intenzo C; Bar-Ad V; Dicker A; Doyle L; Li J; Sato T
    Am J Clin Oncol; 2016 Apr; 39(2):189-95. PubMed ID: 24441583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.
    Gordon AC; Gradishar WJ; Kaklamani VG; Thuluvath AJ; Ryu RK; Sato KT; Gates VL; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2014 Oct; 25(10):1523-32, 1532.e1-2. PubMed ID: 25156827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
    Kousik V; Promila P; Verma R; Gupta A
    Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
    Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
    Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival and Toxicities after
    Emmons EC; Bishay S; Du L; Krebs H; Gandhi RT; Collins ZS; O'Hara R; Akhter NM; Wang EA; Grilli C; Brower JS; Peck SR; Petroziello M; Abdel Aal AK; Golzarian J; Kennedy AS; Matsuoka L; Sze DY; Brown DB
    Radiology; 2022 Oct; 305(1):228-236. PubMed ID: 35762890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases.
    Valsecchi ME; Terai M; Eschelman DJ; Gonsalves CF; Chervoneva I; Shields JA; Shields CL; Yamamoto A; Sullivan KL; Laudadio M; Berd D; Mastrangelo MJ; Sato T
    J Vasc Interv Radiol; 2015 Apr; 26(4):523-32.e2. PubMed ID: 25678394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases.
    Ruohoniemi DM; Zhan C; Wei J; Kulkarni K; Aaltonen ET; Horn JC; Hickey RM; Taslakian B
    J Vasc Interv Radiol; 2020 Aug; 31(8):1233-1241. PubMed ID: 32741550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
    Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
    AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients.
    Fendler WP; Lechner H; Todica A; Paprottka KJ; Paprottka PM; Jakobs TF; Michl M; Bartenstein P; Lehner S; Haug AR
    J Nucl Med; 2016 Apr; 57(4):517-23. PubMed ID: 26742710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of ADC measurements in predicting overall survival in patients undergoing
    Alis D; Durmaz ESM; Gulsen F; Bas A; Kabasakal L; Sager S; Numan F
    Clin Imaging; 2019; 57():124-130. PubMed ID: 31220677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization.
    Levey AO; Elsayed M; Lawson DH; Ermentrout RM; Kudchadkar RR; Bercu ZL; Yushak ML; Newsome J; Kokabi N
    Cardiovasc Intervent Radiol; 2020 Feb; 43(2):254-263. PubMed ID: 31686137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.
    Memon K; Kuzel TM; Vouche M; Atassi R; Lewandowski RJ; Salem R
    Melanoma Res; 2014 Jun; 24(3):244-51. PubMed ID: 24638152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective internal radiation therapy (SIRT) as treatment for hepatic metastases of uveal melanoma: a Finnish nation-wide retrospective experience.
    Tulokas S; Mäenpää H; Peltola E; Kivelä T; Vihinen P; Virta A; Mäkelä S; Kallio R; Hernberg M
    Acta Oncol; 2018 Oct; 57(10):1373-1380. PubMed ID: 29683787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.